| 股票代码：002728 | 股票简称：特一药业 | 公告编号：2023-033 | | --- | --- | --- | | 债券代码：128025 | 债券简称：特一转债 | | （问题征集专题页面二维码） 特此公告。 特一药业集团股份有限公司 关于举行 2022 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特一药业集团股份有限公司定于 2023 年 5 月 10 日（周三）15:00-17:00 在全景网举 办 2022 年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者可 登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长兼总经理许丹青先生、副董事长兼副总经理 许松青先生、财务负责人兼董事会秘书陈习良先生、董事卢北京先生、独立董事曹艳铭 女士、东莞证券保荐代表人郭文俊先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提前向投 资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 ...

Financial Performance - The company's operating revenue for 2022 was CNY 886,570,938.60, representing a 16.94% increase compared to CNY 758,160,497.71 in 2021[20]. - The net profit attributable to shareholders for 2022 was CNY 178,204,104.28, a 40.41% increase from CNY 126,917,422.27 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 171,371,215.85, which is a 51.54% increase from CNY 113,083,086.36 in 2021[20]. - The net cash flow from operating activities was CNY 371,658,160.26, up 44.72% from CNY 256,814,750.48 in the previous year[20]. - The basic earnings per share for 2022 was CNY 0.80, reflecting a 29.03% increase from CNY 0.62 in 2021[20]. - Total assets at the end of 2022 amounted to CNY 2,545,604,654.93, a 23.20% increase from CNY 2,066,196,431.51 at the end of 2021[20]. - The net assets attributable to shareholders at the end of 2022 were CNY 1,403,139,439.55, an 11.21% increase from CNY 1,261,690,115.09 in 2021[20]. - The weighted average return on equity for 2022 was 13.98%, an increase of 2.38% from 11.60% in 2021[20]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of CNY 6.50 per 10 shares, along with a capital reserve increase of 4 shares for every 10 shares held[4]. - The total cash dividend amount for the reporting period is ¥159,514,247.75, which represents 36.34% of the total distributable profit of ¥438,924,757.50[163][160]. - The proposed cash dividend distribution is ¥6.50 per 10 shares (including tax), along with a capital reserve increase of 4 shares for every 10 shares held[162][163]. - The company's profit distribution policy cannot be changed arbitrarily and must be approved by the board and shareholders if adjustments are necessary due to operational conflicts[157]. Market and Industry Trends - The pharmaceutical industry in China is experiencing a shift towards high-quality development, providing opportunities for the company amidst ongoing reforms[29]. - The aging population in China reached 19.8% by the end of 2022, increasing the demand for pharmaceutical products and services[32]. - The company is navigating a complex competitive landscape in the pharmaceutical industry, which presents both challenges and opportunities for growth[32]. Product Development and R&D - The company focuses on the research, production, and sales of traditional Chinese medicine and chemical drugs, positioning itself strategically in the healthcare sector[33]. - The company has 31 invention patents, 33 design patents, and 8 utility model patents as of the end of the reporting period[39]. - Research and development expenses for 2022 were ¥38,009,796.53, a slight increase of 0.62% compared to 2021[62]. - The company has initiated clinical trials for the Skin Disease Blood Detox Pill, aiming to enhance its product portfolio[40]. - The company is committed to the innovation and development of traditional Chinese medicine, aligning with national policies to promote its growth[96]. Sales and Marketing Strategy - The company plans to shift from a distributor model to direct sales to retail terminals to enhance marketing channel effectiveness[38]. - The company’s marketing strategy has been adjusted to increase market expansion and promotional efforts, leading to improved sales performance[42]. - The company aims to enhance marketing capabilities and expand the market share of "Zhi Ke Bao Pian" by deepening existing markets and exploring new ones[98]. Environmental Compliance and Sustainability - The company has made continuous investments in environmental protection to reduce resource consumption and pollution[184]. - The company has a wastewater treatment capacity of 240 tons per day, achieving surface IV class standards for treated wastewater[185]. - The company has obtained pollution discharge permits for its subsidiaries, with validity extending until 2026 and 2027[181]. - The company emphasizes employee rights protection, adhering to labor laws and engaging employees in decision-making processes[195]. Governance and Shareholder Rights - The company maintains complete independence from its controlling shareholder in terms of assets, personnel, finance, organization, and business operations[126]. - The company actively expands communication channels with investors to ensure fair and timely information disclosure, maintaining the rights of shareholders and stakeholders[126]. - The company has established a performance evaluation system for senior management, ensuring that compensation reflects job responsibilities and performance[170]. Future Outlook and Guidance - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion[114]. - The company is exploring potential acquisitions to strengthen its portfolio, with a budget of up to 200 million allocated for this purpose[114]. - The overall market outlook remains positive, with anticipated growth driven by increasing demand for healthcare products and services[114].

Financial Performance - The company's revenue for Q1 2023 reached ¥304,157,421.18, representing a 56.50% increase compared to ¥194,348,090.18 in the same period last year[3] - Net profit attributable to shareholders was ¥105,470,920.94, a significant increase of 130.96% from ¥45,666,688.38 year-on-year[3] - Basic earnings per share rose to ¥0.46, up 119.05% from ¥0.21 in the previous year[3] - Operating profit for the quarter was CNY 127,043,924.70, compared to CNY 54,538,015.75 in Q1 2022, marking an increase of 133.3%[15] - The company’s total comprehensive income for the quarter was CNY 105,470,920.94, up from CNY 45,666,688.38 in the same period last year, indicating a growth of 131.3%[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,498,981,899.98, a decrease of 1.83% from ¥2,545,604,654.93 at the end of the previous year[3] - Cash and cash equivalents at the end of Q1 2023 totaled ¥700,881,200.19, down from ¥739,660,362.06 at the beginning of the year[10] - Total assets as of March 31, 2023, were ¥2,498,981,899.98, a decrease from ¥2,545,604,654.93 at the beginning of the year[12] - Total liabilities decreased to ¥989,721,619.89 from ¥1,142,465,215.38 at the start of the year[12] - The company's equity attributable to shareholders increased to ¥1,509,260,280.09, up from ¥1,403,139,439.55 at the beginning of the year[12] Cash Flow - The company reported a net cash flow from operating activities of ¥26,912,422.14, slightly up by 1.02% from ¥26,640,062.41[3] - Cash flow from operating activities generated a net inflow of CNY 26,912,422.14, slightly up from CNY 26,640,062.41 in the previous year[16] - The net cash outflow from investing activities was CNY -19,235,255.51, compared to CNY -63,112,412.77 in the same period last year[17] - Cash inflow from financing activities totaled CNY 63,918,749.00, a decrease from CNY 229,000,000.00 in Q1 2022[17] Costs and Expenses - Total operating costs for Q1 2023 were ¥180,960,104.90, up 29.2% from ¥140,109,023.79 in Q1 2022[14] - Research and development expenses increased to ¥10,182,147.51, reflecting a rise of 17.7% from ¥8,650,287.50 in the previous year[14] - The company incurred a tax expense of CNY 21,553,510.03, compared to CNY 8,718,235.87 in the previous year, reflecting a growth of 147.0%[15] Market and Growth Strategy - The increase in revenue was primarily driven by a significant rise in pharmaceutical sales, contributing to a gross profit margin increase[5] - The company plans to continue expanding its market presence and investing in new product development to sustain growth[5] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[11] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 67,464, with the largest shareholder holding 31.16% of the shares[7]

Group 1: Company Overview - The company is named Te Yi Pharmaceutical Group Co., Ltd., previously known as Tai Cheng Pharmaceutical [1][12] - The company held an investor relations activity on April 11, 2017, to discuss performance [1] Group 2: Financial Plans and Performance - The company plans to issue convertible bonds, pending shareholder approval [2] - As of December 31, 2016, the company had a total debt of ¥716.61 million and paid ¥17.33 million in interest for the year [7] - The net profit for 2016 was ¥94.78 million, representing a year-on-year growth of 16.86% [11][12] Group 3: Market Position and Sales - Major sales regions include South China (¥276 million, 42.04% of total sales), East China (¥118 million, 18.02%), Northeast (¥68 million, 10.37%), and Central China (¥61 million, 9.27%) [9] - The company maintains stable relationships with its top customers [10] Group 4: Industry Challenges and Opportunities - The company faces challenges due to increased regulation on drug prices and quality, but this also presents opportunities for stronger companies [3] - The company is considering mergers and acquisitions to enhance competitiveness and risk resistance [4] Group 5: Innovation and Development - The company has not established plans for a merger fund but is open to future opportunities [2] - There are no current plans to explore new fields outside the pharmaceutical industry [6] Group 6: Investor Relations and Shareholder Returns - The company aims to continuously reward shareholders through dividends and other means within regulatory frameworks [8] - The company is committed to improving its market value management and enhancing shareholder returns [10]

证券代码：002728 证券简称：特一药业 公告编号：2022-068 特一药业集团股份有限公司 TEYI PHARMACEUTICAL GROUP CO.,LTD （注册地址：台山市台城长兴路9、11号） 2022 年第三季度报告 2022 年 10 月 □是 否 2022 年第三季度报告 特一药业集团股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |---------------------------------------------------- ...

特一药业集团股份有限公司 TEYI PHARMACEUTICAL GROUP CO.,LTD （注册地址：台山市台城长兴路9、11号） 2022 年半年度报告 2022 年 8 月 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人许丹青、主管会计工作负责人陈习良及会计机构负责人(会计 主管人员)蔡壁坚声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 敬请投资者注意投资风险。 公司在本报告"第三节-管理层讨论与分析"中"十、公司面临的风险和 应对措施"中部分详细描述了公司未来经营中可能存在的风险及应对措施， 敬请投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 2022 年半年度报告全文 | --- | --- | |--------------------------------------- ...

特一药业集团股份有限公司 TEYI PHARMACEUTICAL GROUP CO.,LTD （注册地址：台山市台城长兴路9、11号） 2022 年半年度报告 2022 年 8 月 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人许丹青、主管会计工作负责人陈习良及会计机构负责人(会计 主管人员)蔡壁坚声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 敬请投资者注意投资风险。 公司在本报告"第三节-管理层讨论与分析"中"十、公司面临的风险和 应对措施"中部分详细描述了公司未来经营中可能存在的风险及应对措施， 敬请投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 2022 年半年度报告全文 | --- | --- | |--------------------------------------- ...

2022 年第一季度报告全文 股票简称：特一药业 债券简称：特一转债 股票代码：002728 公告编号：2022-026 债券代码：128025 特一药业集团股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| ...

特一药业集团股份有限公司 TEYI PHARMACEUTICAL GROUP CO.,LTD （注册地址：台山市台城长兴路9、11号） 2021 年年度报告 2022 年 3 月 2021 年年度报告全文 股 0 股（含税），不以公积金转增股本。 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人许丹青、主管会计工作负责人陈习良及会计机构负责人(会计主 管人员)蔡壁坚声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 敬请投资者注意投资风险。 | --- | --- | |-------|--------------------------------------------------------------------------| | | | | | 公司在本报告第三节"管理层讨论与分析"中"十一、公司未来发展的展 | | | 望"部分，详细描述了公司经营 ...

特一药业集团股份有限公司 TEYI PHARMACEUTICAL GROUP CO.,LTD （注册地址：台山市台城长兴路9、11号） 2021 年第三季度报告 2021 年 10 月 □ 是 √ 否 2021 年第三季度报告 债券代码：128025 债券简称：特一转债 特一药业集团股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人许丹青、主管会计工作负责人陈习良及会计机构负责人（会计主管人员） 蔡壁坚声明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 1 股票代码：002728 股票简称：特一药业 公告编号：2021-061 | --- | --- | --- | --- | --- | |------------- ...